FZMD · Fuse Medical, Inc. · Documents

Sep 27

Current report 8-K Events of Aug 14

Financial results

Aug 15

Current report 8-K Events of Aug 14

Financial results

Aug 14

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $5M ▲ 7.0% Net income $307.59K

Jun 26

Current report 8-K Events of Jun 23

Shareholder vote results

May 15

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $3.98M ▼ 12.5% Net loss $228.36K Diluted EPS $0.00

May 10

Proxy statement DEF 14A Meeting Jun 23, 2023

Proxy statement

May 10

Proxy statement DEFA14A

Proxy statement

May 10

Annual report to holders ARS

Annual report to holders

Apr 18

Current report 8-K Events of Apr 14

Financial results

Apr 14

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $18.64M ▼ 8.7% Net income $3.1M Diluted EPS $0.04

Apr 3

Late filing notice NT 10-K

Late filing notice

Nov 22

Current report 8-K Events of Nov 17

Change of auditor

Nov 18

Current report 8-K Events of Nov 15

Financial results

Nov 14

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $4.54M ▲ 6.7% Net loss $9376

Aug 11

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $4.67M ▼ 17.6% Net loss $93.32K

Jun 28

Current report 8-K Events of Jun 23

Shareholder vote results

May 12

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Revenue $4.55M ▲ 2.6% Net loss $358.28K

May 10

Proxy statement DEF 14A Meeting Jun 23, 2022

Proxy statement

May 10

Proxy statement DEFA14A

Proxy statement

Apr 8

Current report 8-K Events of Apr 4

Director or officer change, or executive pay

Mar 31

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Revenue $20.41M ▼ 4.6% Net loss $1.59M Diluted EPS -$0.02

Dec 20

Current report 8-K Events of Dec 14

New debt or off-balance-sheet obligation

Dec 3

Current report 8-K Events of Nov 29

Director or officer change, or executive pay

Nov 12

Current report 8-K Events of Nov 10

Entered into a material agreement

Nov 10

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Revenue $4.25M ▼ 25.9% Net loss $697.04K Diluted EPS -$0.01

Aug 12

Quarterly report 10-Q FY2021 Q2, ended Jun 30

Quarterly report for FY2021 Q2

Revenue $5.67M ▲ 41.2% Net loss $85.48K

Jun 10

Current report 8-K Events of Jun 9

Shareholder vote results

May 12

Quarterly report 10-Q FY2021 Q1, ended Mar 31

Quarterly report for FY2021 Q1

Revenue $4.44M ▼ 4.2% Net loss $453.32K

Apr 27

Proxy statement DEF 14A Meeting Jun 9, 2021

Proxy statement

Apr 27

Proxy statement DEFA14A

Proxy statement

Mar 31

Annual report 10-K FY2020, ended Dec 31

Annual report for FY2020

Revenue $21.4M ▼ 6.6% Net loss $1.43M Diluted EPS -$0.02

Feb 1

Current report 8-K

Other events

Jan 20

Current report 8-K Events of Jan 14

Other events

Dec 22

Current report 8-K

Other events

Nov 16

Quarterly report 10-Q FY2020 Q3, ended Sep 30

Quarterly report for FY2020 Q3

Revenue $5.74M ▲ 0.4% Net income $80.48K Diluted EPS $0.00

Aug 14

Current report 8-K Events of Aug 10

Other events

Aug 7

Quarterly report 10-Q FY2020 Q2, ended Jun 30

Quarterly report for FY2020 Q2

Revenue $4.01M ▼ 21.0% Net loss $423.43K

Jun 19

Current report 8-K Events of Jun 15

Change of auditor, Other events

Jun 10

Current report 8-K Events of Jun 9

Shareholder vote results

May 22

Quarterly report 10-Q FY2020 Q1, ended Mar 31

Quarterly report for FY2020 Q1

Revenue $4.64M ▼ 2.8% Net loss $1.28M

May 15

Late filing notice NT 10-Q

Late filing notice

May 13

Current report 8-K Events of May 6

Entered into a material agreement, New debt or off-balance-sheet obligation

Apr 27

Proxy statement DEF 14A Meeting Jun 9, 2020

Proxy statement

Apr 27

Proxy statement DEFA14A

Proxy statement

Mar 30

Annual report 10-K FY2019, ended Dec 31

Annual report for FY2019

Revenue $22.9M ▼ 13.1% Net loss $3.32M Diluted EPS -$0.05